In addition, nearly all the patients with CML in our present analysis demonstrated both mono‐ and polyfunctional T‐cell cytokine responses to SARS‐CoV‐2, a response that is similar to healthy controls tested in previous trials of BNT162b2 vaccination,6 although it should be noted that methodology differs between studies. This evidence concerns the gene TBXT and chronic myelogenous leukemia, BCR-ABL1 positive.